Ludwig Institute for Cancer Research Limited

Universitè Catholique De Louvain

Argenx Bvba

Oxford University Innovation Ltd

Other

Institut National De La Sante Et De La Recherche Medicale

Institut Gustave Roussy

Ludwig Institute of Cancer Research

Université Catholique De Louvian

Argenx Bv

Pierre G Coulie

Thierry R Boon-Falleur

Pierre Van Der Bruggen

Jean-Christophe Renauld

Sophie Lucas

Aline Van Pel

Vincent Brichard

Etienne De Plaen

Sebastian Paul Van Der Woning

Thomas Wolfel

Donata Rimoldi

Hideyuki Ikeda

Victor Jongeneel

Claude Wildmann

Gitte De Boeck

Stefan Carrel

Daryl Reed

Jean-Charles Cerrottini

Bernard Lethe

Judy Bastin

Alan Townsend

Jean Herman

Jean-Christope Renauld

Torsten Dreier

Laure Dumoutier

Nicolas Van Baren

Charles DeSmet

Filip Borgions

Lore Mariën

Thomas Gajewski

Julia Cuende Villasur

Thomas W&ouml;lfel

Benoit Van Den Eynde

Jacques Van Snick

Catia Traversari

Hans De Haard

Catherine Uyttenhove

Michael Saunders

Etienne DePlaen

Catherine Druez

Pascale Boel

Immanuel Luescher

Catherine Germeau

Pascale Bo{haeck Over (e)}l

Wenbin Ma

Stéphanie Liénart

Fathia Mami-Chouaib

Jean-Pierre Szikora

Cornelis J M Melief

Bernard Leth&eacute;

Pascale Bo&euml;l

Martin W Kast

Marjan J W Visseren

Thierry Boon Falleur

Nathalie Vigneron

Vincent Stroobant

Faten El Hage

Stéphanie Lienart

Stëphanie Liénart

Stephanie Lienart

Lore Marien

Lore MARIËN

The present invention relates to a protein binding to GARP in the presence of TGF-&#x3b2; and uses thereof.

Anti-GARP protein

The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-&#x3b2;1, particularly a complex of human GARP and human TGF-&#x3b2;1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-&#x3b2; from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.

Nucleic acids encoding GARP-TGF-beta 1 antibodies

Method of screening for anti-GARP antibodies

GARP-TGF-&#x3b2; 1 IGG antibodies

Antibody against a complex between human GARP and latent TGF-&#x3b2;

GARP-TGF-beta 1 antibodies

The present invention relates to an antibody binding to the transmembrane protein 'glycoprotein A repetitions predominant' (GARP) in the presence of TGF-&#x3b2; and uses thereof.

Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody

The present invention is related to Preprocalcitonin antigen T epitopes, presented by the Major Histocompatibility Complex I (MHC I). These peptides can be used in cancer immunotherapy.

Preprocalcitonin antigen T epitopes

This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, &#x2203;microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.

MAGE-C2 antigenic peptides and uses thereof

This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, &#x3b2;microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.

The invention describes HERV-AVL3-B tumor associated genes, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a HERV-AVL3-B gene product.

Endogenous retrovirus tumor associated nucleic acids and antigens

Complexes of SEQ ID NO: 12 and HLA-A2 can be used to generate CTLs. They can be supplemented with IL-6 and IL-12.

Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules

Peptides which satisfy the formula of SEQ ID NO: 10 bind to HLA-Cw*1601 molecules, and stimulate proliferation of cytolytic T cells. Examples of such peptides are those set forth in SEQ ID NOS: 4 and 5.

METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HLA-CW 1601/MAGE-1 DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS

The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS

A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.

Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens

Growing community of inventors

Brussels, Belgium

Pierre G Coulie